novartis glp-1 receptor agonist weight management diabetes treatments Heterogeneity in response to agonists in type 2 in real-world clinical practice: insights from the DPV register – an IMI-SOPHIA study | Diabetologia The GLP-1 Agonists and Obesity:

Discover the serious yet rare side effects of Ozempic, including pancreatitis, thyroid cancer, and more, plus expert insights.

Mounjaro is a newer option that targets two hormones and can be discussed with healthcare providers for suitable treatment plans

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are two gut hormones, defined incretins, responsible for the amplification of insulin secretion after oral glucose intake

This review summarizes current evidence on the nutritional implications of GLP1-based pharmacotherapy in adults with obesity, including common gastrointestinal adverse events, reduced energy intake, potential macro and micronutrient inadequacies, and risks of lean mass loss